PDF herunterladen
Exp Clin Endocrinol Diabetes 2007; 115(5): 281-286
DOI: 10.1055/s-2007-977696
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Impact of the Leu7Pro Polymorphism of preproNPY on Diurnal NPY and Hormone Secretion in Type 2 Diabetes

U. Jaakkola 1 , 2 , M. Koulu 1 , M. K. Karvonen 3 , 4 , H. Seppälä 2 , U. Pesonen 1 , T. Vahlberg 5 , J. Kallio 1 , 6
  • 1Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
  • 2Department of Ophthalmology, Turku City Hospital, Turku, Finland
  • 3Hormos Medical Corporation, Turku, Finland
  • 4Turku Health Care Center, Turku, Finland
  • 5Department of Biostatistics, University of Turku, Turku, Finland
  • 6Centre for Biotechnology, University of Turku, Turku, Finland
Weitere Informationen

Publikationsverlauf

received 19. 12. 2005 first decision 9. 2. 2006

accepted 15. 2. 2006

Publikationsdatum:
21. Mai 2007 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Neuropeptide Y (NPY) is a sympathetic neurotransmitter that plays a role in e.g. circulation, hormone release and angiogenesis. Earlier studies have shown that the Leucine 7 to Proline 7 (Leu7Pro) polymorphism of preproNPY is associated with increased risk for vascular complications in type 2 diabetes. The mechanism for this maybe altered transmitter and hormone levels or altered cardiovascular functions, which have been observed in healthy subjects having the Leu7Pro polymorphism. The current study was undertaken to explore if the Leu7Pro polymorphism has an impact on these functions in subjects with type 2 diabetes. Diurnal measurements were performed for Finnish Caucasian type 2 diabetes patients of two preproNPY genotypes (matched by sex, age, BMI, duration of diabetes and HbA1c) in resting position to prevent sympathetic stimulation. Standard meals were offered during the 24-hour study period. Nine subjects with the Leu7Pro polymorphism and ten subjects without this polymorphism were studied. Plasma concentrations of NPY, glucose, insulin, cortisol, prolactin and leptin were measured by taking blood samples at 20 time points (from 8 a.m. to 8 a.m.). Heart rate and blood pressure were measured at the same time points. The results show that NPY concentrations were similar in both preproNPY genotypes. Glucose, insulin, cortisol and leptin concentrations as well as heart rate and blood pressure were also similar. However, a significant difference between genotypes was found in the association of NPY concentrations with cortisol concentrations (p for difference=0.002). Also a statistically significant negative association of plasma NPY levels with plasma glucose levels was found in both genotypes. Since no impact of preproNPY genotype on mean NPY or hormone levels were detected in subjects with type 2 diabetes, the mechanisms for the increased risk for diabetic complications in the subjects with the Leu7Pro polymorphism need to be further explored.

Key words

NPY polymorphism - diabetes - hormone secretion

References

  • 1 Arreola F, Paniagua R, Herrera J, Diaz-Bensussen S, Mondragon L, Bermudez JA, Perez Pasten E, Villalpando S. Low plasma zinc and androgen in insulin-dependent diabetes mellitus.  Arch Androl. 1986;  16 151-154
    PubMedSuche in Google Scholar
  • 2 Bernardi L, Ricordi L, Lazzari P, Solda P, Calciati A, Ferrari MR, Vandea I, Finardi G, Fratino P. Impaired circadian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease.  Circulation. 1992;  86 1443-1452
    PubMedSuche in Google Scholar
  • 3 Bischoff A, Michel MC. Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype.  Endocrinology. 1998a;  139 3018-3021
    CrossrefPubMedSuche in Google Scholar
  • 4 Bischoff A, Michel MC. Renal effects of neuropeptide Y.  Pflugers Arch. 1998b;  435 443-453
    PubMedSuche in Google Scholar
  • 5 Brelje TC, Scharp DW, Lacy PE, Ogren L, Talamantes F, Robertson M, Friesen HG, Sorenson RL. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy.  Endocrinology. 1993;  132 879-887
    CrossrefPubMedSuche in Google Scholar
  • 6 Castan I, Valet P, Quideau N, Voisin T, Ambid L, Laburthe M, Lafontan M, Carpene C. Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes.  Am J Physiol. 1994;  266 R1141-1147
    PubMedSuche in Google Scholar
  • 7 Ding B, Kull B, Liu Z, Mottagui-Tabar S, Thonberg H, Gu HF, Brookes AJ, Grundemar L, Karlsson C, Hamsten A, Arner P, Ostenson CG, Efendic S, Monne M, von Heijne G, Eriksson P, Wahlestedt C. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function.  Regul Pept. 2005;  127 45-53
    CrossrefPubMedSuche in Google Scholar
  • 8 Ding B. Distribution of the NPY 1128C allele frequency in different populations.  J Neural Transm. 2003;  110 1199-1204
    CrossrefPubMedSuche in Google Scholar
  • 9 Djursing H, Nyholm HC, Hagen C, Molsted-Pedersen L. Depressed prolactin levels in diabetic women with anovulation.  Acta Obstet Gynecol Scand. 1982;  61 403-406
    PubMedSuche in Google Scholar
  • 10 Holstad M, Sandler S. Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice.  J Endocrinol. 1999;  163 229-234
    CrossrefPubMedSuche in Google Scholar
  • 11 Jaakkola U, Kuusela T, Jartti T, Pesonen U, Koulu M, Vahlberg T, Kallio J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine during oral glucose-tolerance test.  J Clin Endocrinol Metab. 2005;  90 3646-3652
    CrossrefPubMedSuche in Google Scholar
  • 12 Jansson PA, Eliasson B, Lindmark S, Eriksson JW. Endocrine abnormalities in healthy first-degree relatives of type 2 diabetes patients-potential role of steroid hormones and leptin in the development of insulin resistance.  Eur J Clin Invest. 2002;  32 172-178
    CrossrefPubMedSuche in Google Scholar
  • 13 Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y.  J Clin Endocrinol Metab. 2003;  88 3278-3283
    CrossrefPubMedSuche in Google Scholar
  • 14 Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.  FASEB J. 2001a;  15 1242-1244
    PubMedSuche in Google Scholar
  • 15 Kallio J, Pesonen U, Karvonen MK, Kojima M, Hosoda H, Kangawa K, Koulu M. Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY.  J Clin Endocrinol Metab. 2001b;  86 5348-5352
    CrossrefPubMedSuche in Google Scholar
  • 16 Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men.  Atherosclerosis. 2001;  159 145-151
    CrossrefPubMedSuche in Google Scholar
  • 17 Karvonen MK, Koulu M, Pesonen U, Uusitupa MI, Tammi A, Viikari J, Simell O, Ronnemaa T. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children.  J Clin Endocrinol Metab. 2000;  85 1455-1460
    CrossrefPubMedSuche in Google Scholar
  • 18 Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels.  Nat Med. 1998;  4 1434-1437
    PubMedSuche in Google Scholar
  • 19 Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, Geng Y, Karvonen MK, Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee EW, Higgins RD, Zukowska Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization.  Ann Med. 2004;  36 232-240
    CrossrefPubMedSuche in Google Scholar
  • 20 Li S, Hong M, Fournier A, St-Pierre S, Pelletier G. Role of neuropeptide Y in the regulation of gonadotropin-releasing hormone gene expression in the rat preoptic area.  Brain Res Mol Brain Res. 1994;  26 69-73
    PubMedSuche in Google Scholar
  • 21 McCulloch CE, Searle SR. Generalized, Linear, and Mixed Models. John Wiley & Sons, New York 2001
  • 22 Morgan DG, Kulkarni RN, Hurley JD, Wang ZL, Wang RM, Ghatei MA, Karlsen AE, Bloom SR, Smith DM. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells.  Diabetologia. 1998;  41 1482-1491
    CrossrefPubMedSuche in Google Scholar
  • 23 Nilsson T, Lind H, Brunkvall J, Edvinsson L. Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent.  Can J Physiol Pharmacol. 2000;  78 251-255
    CrossrefPubMedSuche in Google Scholar
  • 24 Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa MI. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects.  J Clin Endocrinol Metab. 2000a;  85 2266-2269
    CrossrefPubMedSuche in Google Scholar
  • 25 Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2000b;  108 235-236
    Thieme ConnectPubMedSuche in Google Scholar
  • 26 Nordman S, Ding B, Ostenson CG, Karvestedt L, Brismar K, Efendic S, Gu HF. Leu7Pro Polymorphism in the Neuropeptide Y (NPY) Gene is Associated with Impaired Glucose Tolerance and Type 2 Diabetes in Swedish Men.  Exp Clin Endocrinol Diabetes. 2005;  113 282-287
    Thieme ConnectPubMedSuche in Google Scholar
  • 27 Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH. FinnDiane Study Group . Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients.  Diabetes Care. 2004;  27 503-509
    PubMedSuche in Google Scholar
  • 28 Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease?.  J Neuroimmunol. 2002;  126 116-125
    CrossrefPubMedSuche in Google Scholar
  • 29 Uckaya G, Ozata M, Bayraktar Z, Erten V, Bingol N, Ozdemir IC. Is leptin associated with diabetic retinopathy?.  Diabetes Care. 2000;  23 371-376
    CrossrefPubMedSuche in Google Scholar
  • 30 Wallerstedt SM, Skrtic S, Eriksson AL, Ohlsson C, Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population.  J Hypertens. 2004;  22 1277-1281
    CrossrefPubMedSuche in Google Scholar
  • 31 Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium.  Circ Res. 1998;  83 187-195
    PubMedSuche in Google Scholar
  • 32 Zukowska-Grojec Z, Neuropeptide Y. A novel sympathetic stress hormone and more.  Ann N Y Acad Sci. 1995;  771 219-233
    CrossrefPubMedSuche in Google Scholar

Correspondence

U. JaakkolaMD 

Department of Pharmacology, Drug Development and Therapeutics

University of TurkuItäinen Pitkäkatu 4

20520 Turku

Finland

Telefon: +358/50/546 23 28

Fax: +358/2/333 72 16

eMail: ulriikka.jaakkola@utu.fi